Durata Therapeutics (NASDAQ: DRTX) today announced the appointment of Allison Wey as the company’s vice president of Investor Relations and Public Affairs. Ms. Wey, who joined the company’s Chicago office today, brings to Durata more than 25 years of experience in investor relations, financial communications and corporate communications. “We welcome Allison to our senior management team as we enter a critical period of the company’s development,” said Durata Chief Executive Officer Paul R. Edick. “Three months into our progression as a public company, and as we approach significant clinical, regulatory and commercialization milestones that will be important drivers of the company’s value, Allison will contribute greatly to Durata’s growth and success.” Before joining Durata, Ms. Wey served as vice president, Investor Relations and Corporate Affairs of Par Pharmaceuticals until its recent acquisition by TPG. She also served as vice president, Investor Relations and Corporate Communications at Boron, LePore & Associates, Inc. Previously, Ms. Wey served as senior vice president at Edelman Financial Worldwide; managing director, Financial Communications Group, Hill and Knowlton; director of Aftermarket Services, Equity Capital Markets at Bear, Stearns & Co., Inc.; and trading floor reporter for the American Stock Exchange. Ms. Wey earned her B.A. in Economics/Marketing from Drake University. About Durata Therapeutics Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Durata is currently enrolling and dosing patients in two global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI. Forward-looking statements Any statements in this press release about Durata’s future expectations, plans and prospects constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Durata anticipates that subsequent events and developments will cause its views to change. However, while Durata may elect to update these forward-looking statements at some point in the future, Durata specifically disclaims any obligation to do so.